Table 3.
Reported cases of SLE after COVID-19 vaccination.
| Author | Age | Gender | PMH | Timeline of symptom onset | Type of Vaccine | Scoring of SLE | Serology profile | Diagnose |
|---|---|---|---|---|---|---|---|---|
| Patil | 22 | F | infective jaundice (non-B) | 2 wk after 1st dose | Viral vector | 22 | ANA,anti-dsDNA | SLE with anemia of chronic diseases |
| Nune | 24 | M | N | 2 wk after 2nd dose | mRNA | 21 | ANA,anti-dsDNA, low C3 and C4 | SLE withn ecrotizing lymphadenitis |
| Hidaka | 53 | F | Bronchial asthma, Vogt–Koyanagi–Harada disease, Hashimoto disease | few days after 1st and 2nd dose | mRNA | 20 | ANA, low C3 and C4 | SLE with Evans syndrome |
| Gamonal | 27 | F | N | 3 wk after 2nd dose | Viral vector | 21 | ANA,anti-dsDNA, anti-Sm,anti-SSA, low C3 and C4 | SLE with AA |
| Rios | 42 | F | three pregnancies with two spontan-eous abortions | 2 wk after 1st dose | mRNA | 18 | ANA,anti-dsDNA, low C4 | SLE with secondary APS |
| Wang | 37 | F | N | 2 wk after 1st dose | Viral vector | 12 | ANA, anti-dsDNA, low C3 | SLE with acrocyanosis |
| Mousa | 22 | F | N | 1 wk after 1st dose | mRNA | 25 | ANA, anti-dsDNA, low C3 and C4 | SLE with acute pancreatitis vasculitic rash |
| Raviv | 24 | M | N | 2 days after 1st dose | mRNA | 21 | ANA,anti-Rib-P, anti-chromatin (nucleosomal), low C3 | SLE |
| Báez | 27 | F | type 1 diabetes mellitus | 2 wk after 2nd dose | mRNA | 19 | ANA,anti-SSA,anti-SSB, anti-dsDNA,low C4 | SLE |
| Lemoine | 68 | M | N | 2 days after 1st dose | mRNA | 12 | ANA,anti-dsDNA, p-ANCA with anti-MPO specificity | SLE |
| Khanna | 18 | F | autism | 1 wk after 1st dose | mRNA | 19 | ANA,anti-RNP, anti-Sm, low C3 and C4 | SLE |
| Ghang | 20 | F | N | 10 days after 1st dose | mRNA | 14 | ANA,anti-SSA, anti-SSB | SLE |
F, female; M, male; ANA,anti-nuclear antibody; anti-dsDNA,antibody recognizing double-strandded DNA; anti-SSA,anti-Sjgren syndrome A antibody; anti-SSB,anti-Sjgren syndrome B antibody; anti-RNP,anti-ribonuclear protein antibody;anti-Sm,anti-Smith antibody; anti-Rib-P, anti-ribosomal P protein antibody; C3, complement 3; C4,complement 4; SLE, systemic lupus Erythematosus; AA,alopecia areata;APS, antiphospholipid syndrome; PMH, past medical history. Scoring of SLE is based on the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria.